Commentary: The best acellular pertussis vaccines are multicomponent

Pediatric Infectious Disease Journal

Volumn 16, Issue 5, 1997, Pages 517-519

  Olin, Patrick ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

Acellular pertussis vaccine; Pertussis; Whole cell vaccine

Indexed keywords

EID: 0001491515     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/00006454-199705000-00012     Document Type: Article

References (17)

1. Halsey NA. New developments with pertussis vaccines. Pediatrics 1995;96:970-1.
2. Edwards KM, Decker MD. Acellular pertussis vaccines for infants. N Engl J Med 1996;334:391-2 and authors' reply to letters. N Engl J Med 1996;334:1547-8.
3. Poland GA. Acellular pertussis vaccines: new vaccines for an old disease. Lancet 1996;347:209-10.
4. Fox JL. FDA approves first acellular pertussis vaccines for infants. Nature Med 1996;2:953.
5. Schneerson R, Robbins JB, Taranger J, Lagergård T, Trollfors B. A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned. Lancet 1996;348:1289-92 and authors' reply to letters. Lancet 1997;349:137-8.
6. Simondon F. Sénégal Pertussis Trial. Trial Synopsis. International Symposium on Pertussis Vaccine Trials, October 30 to November 1, 1995. Rome: Istituto Superiore di Sanità. Dev Biol Stand (in press).
7. Heininger U. A comparative efficacy trial in Germany in which children received either the Lederle/Takeda acellular component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Trial Synopsis. International Symposium on Pertussis Vaccine Trials, October 30 to November 1, 1995. Rome: Istituto Superiore di Sanità. Dev Biol Stand (in press).
8. Schmitt HJ, Wirsing von König CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in infants after household exposure. JAMA 1996;275:37-41.
9. Liese JG, Harzer E, Meschievitz CK, et al. Case-control study to evaluate the efficacy of Biken acellular pertussis vaccine combined with diphtheria and tetanus toxoids (DTacP) in infants [Abstract]. Presented at the First International Pediatric Infectious Disease Conference, Monterey, CA, 1995.
10. Gustafsson L, Hallander H, Olin P, Reizenstein E, Storsaeter J. Pertussis vaccine Trial I: Technical report with preplanned analyses of safety, efficacy and immunogenicity. SMI-tryck No. 105. Stockholm: Swedish Institute for Infectious Disease Control, 1995.
11. Greco D, Salmaso S, Mastrantonio P, et al. Clinical efficacy, immunogenicity and safety of two acellular and one whole-cell pertussis vaccines: results from the Italian Trial. N Engl J Med 1996;334:341-8.
12. Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden: protective efficacy and adverse events. Lancet 1988;1:955-60.
13. Anonymous. A clinical trial of acellular pertussis vaccines in Sweden. Technical Report. Stockholm: National Bacteriological Laboratory, 1988.
14. Storsaeter J, Hallander H, Farrington CP, Olin P, Möllby R, Miller E. Secondary analyses of the efficacy of two acellular pertussis vaccines in a Swedish Phase III trial. Vaccine 1990;8:457-61.
15. Trollfors B, Taranger T, Lagergård T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995;333:1045-50.
16. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular and a whole-cell pertussis vaccine. N Engl J Med 1996;334:349-55.
17. Olin P, Rasmussen F, Gottfarb P. Vaccination schedule and protection: simultaneous vaccination and safety-experiences from recent controlled pertussis trials. Int J Infect Dis 1997;1:143-7.